期刊文献+

Extra-pleural pneumonectomy in the setting of tri-modality therapy for patients with malignant pleural mesothelioma

Extra-pleural pneumonectomy in the setting of tri-modality therapy for patients with malignant pleural mesothelioma
下载PDF
导出
摘要 Although declining in the US due to restrictions of asbestos exposure, malignant pleura/mesothelioma (MPP) remains a very serious thoracic malignancy that is rising in incidence worldwide (1). Trirnodality therapy with chemotherapy and radiotherapy combined with extrapleural pneumonectomy (EPP) has gained acceptance given the acceptable mortality rate (〈5%) and long term survival reported in patients with epithelial histology, negative margins, and no extrapleural lymph node involvement after trimodalitv treatment (2). Although declining in the US due to restrictions of asbestos exposure, malignant pleura/mesothelioma (MPP) remains a very serious thoracic malignancy that is rising in incidence worldwide (1). Trirnodality therapy with chemotherapy and radiotherapy combined with extrapleural pneumonectomy (EPP) has gained acceptance given the acceptable mortality rate (〈5%) and long term survival reported in patients with epithelial histology, negative margins, and no extrapleural lymph node involvement after trimodalitv treatment (2).
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第2期128-129,共2页 中国癌症研究(英文版)
  • 相关文献

参考文献8

  • 1Chi A, Liao Z, Nguyen NP, et al. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modali9, treatment of malignant pleural mesothelioma. J Thorac Oncol 2011;6:1132-41.
  • 2Sugarbaker DJ, Flores RM, Jaklitsch M'I, et al. Resection margins, extrapleural nodal status, and cell .type determine postoperative long-term survival in trimodality therapy ofmalignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-5.
  • 3Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-6, 626.el-3.
  • 4Lang-Lazdunski L, Bille A, Lal R, et al. Pleurect()my/ decortication in superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural nlesothelioma. J Thorac Oncol 2012;7:737-43.
  • 5Treasure :I, Lang-Lazdunski L, Waller D, et al. Extra- pleural pneumonectomy versus no ext:a-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study: Lancet Oncol 2011;12:763-72.
  • 6Cao C, Tian D, Manganas C, et al. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann Cardiothorac Surg 2012;1:428-37.
  • 7Tonoli S, Vltali P, Scotti :, et al. Adjuvant radiotheraW after extrapleural pneumonectomy for mesothelioma. Prospective analysis of a multi-institutional series. Radiother Oncol 2011;101:311-5.
  • 8Minatel E, Trovo M, Polesel J, et al. Toinotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung. J Thorac Oncol 2012;7:1862-6.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部